Immune thrombocytopenic purpura in infacy

Key Findings & Data:It is an autoimmune disease characterized by skin and mucosal bleeding as a result of increased platelet destruction due to antiplatelet antibodies in the plasma.

💡

Conclusion & Impact:Vaccination should be kept inmind in the etiology of immune thrombocytopenic purpura besides infections.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Immune thrombocytopenic purpura is the most frequent cause of childhood thrombocytopenia. It is an autoimmune disease characterized by skin and mucosal bleeding as a result of increased platelet destruction due to antiplatelet antibodies in the plasma. In this study, 12 patients diagnosed as acute immune thrombocytopenic purpura, are retrospectively evaluated in terms of their ages, etiologies, laboratory findings and treatment methods. The ages of the patients were between 1-12 months (mean 5,21±2,8 month). Mean platelet count at the time of diagnosis was 15333 ±11499 /mm3. Five cases (41,6%) had an infection history and two (40%) of them was infected with cytomegalovirus. Two of the cases (16,6%) had a vaccination history. Six cases (50%) were treated with intravenous immumnogiobubin, and 4 cases (34%) were treated with high dose methylprednisonolone. In two of the patients (16,6%) spontaneous remission was observed. Immune thrombocytopenic purpura in infancy was retrospectively evaluated in this study. Vaccination should be kept inmind in the etiology of immune thrombocytopenic purpura besides infections.

Özet

Immun trombositopenik purpura çocukluk çağı trombositopenilerinin en sık nedenidir. Plazmada antitrombosit antikorlara bağlı artmış trombosit yıkımı ile karakterize, deri ve mukoza kanamaları ile seyreden otoimmun bir hastalıktır. Çalışmamızda akut immun trombositopenik purpura tanısı alan 12 olgu tanı yaşları, etyolojileri, klinik ve laboratuar özellikleri ve tedavileri açısından retrospektif olarak incelendi. Olguların yaşları 1-12 ay arasında, ortalama 5,21±2,8 ay idi. Tanı anında ortalama trombosit sayısı 15333 ±11499/mm3 idi. Beş olguda (%41,6) infeksiyon öyküsü mevcuttu; bunların ikisinde (%40) sitomegalovirus enfeksiyonu tespit edildi. İki olguda ise (%16,6) yaklaşık iki hafta önce aşılanma öyküsü mevcuttu. Altı olguya (%50) intravenöz immunglobulin, 4 olguya (%33,3) yüksek doz metilprednisolon tedavisi uygulandı. İki olguda (%16,6) spontan remisyon gözlendi. Bu çalışmada, süt çocukluğu döneminde görülen immun trombositopenik purpura olguları literatür ışığında retrospektif olarak değerlendirildi. Enfeksiyöz etkenler yanında aşılanmanın da etyolojideki yeri hatırlatılmak istendi.

🔖

Cite This Article

İPEK, Ö. İ., BOZAYKUT, A., SEREN, P. L., ÇAĞRIL, S. C. (2022). Immune thrombocytopenic purpura in infacy. Ege Pediatri Bülteni, Cilt: 12 - Sayı: 2, 89–94. https://ajindex.com/articles/495753

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Immun trombositopenic purpura, 40. Türk Pediatri Kongresi, İstanbul, 21-25 Haziran 2004: 117-126. Yu-Waye Chu7 MD, James Korb, And Kathleen M. Sakamato, MD. Idopathic Trombocytopenic Purpura. Pediatrics in Review 2000; 21(3): 95-103. Williams WJ. Classification of disorders of hemostasis. In: Haematology, 1st ed. Singapore: 1986: 1288-1289.
Beardsley DS, Nathan DQ, Platelet abnormalities in childhood. In: Nathan DG, Orkin SH, (eds). Hematology of Infancy and Childhood, 5th ed. Philedelphia: WB Saunders Company, 1998; 1574-1585.
Imbach P, Blanchette VS, Nugent D, Kühne T. Immun trombocytopenic purpura: immediate and long-term effects of intravenous immunoglobulin. In: Kazatchkine MD, Morell A, (eds). Intravenous Immunoglobulin Resarch and Therapy. Interlaken: Parthhenon Publishing, 1996; 135-141. Lanzkowsky P: Disorders of Platelets. Churchill Livingstone. In: Manual of Pediatrics Hematology and Oncology. Ed. By P.Lanzkowsky, New York, London 1999, 3th edition, 233-286.
Sandoval C, Visintainer P, Özkaynak MF, Tugal O, Jayabose S. Clinical features and treatment outcomes of 79 infants with ITP. Pediatr Blood Cancer 2004; 42(1): 109-112.
Mizutani K, Azuma E, Komada Y et al. An infantile case of CMV induced ITP with predominant proliferation of CD10 positive lymphoblast in bone marrow. Acta Paediatr Jpn 1995; 37(1): 71-74.
Mousalem M, Yasinse N. Immune thrombocytopenic purpura in childhood: a Lebanese perspective. Mol Immunol 2003; 39(17-18): 1105-1107.
Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. Br J Clin Pharmacol 2003; 55(1): 107-111.
Miller E, Waight P, Farrington CP, Andrews N, Stowe J Talor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84(3): 227-229.
Bithell TC, Disorders of Hemostasis and Coagulation, Idiopathic Thrombocytopenic Purpura. In: Lee QR, Bithell TC, Foerster S, Athens JW,Lukens JN(eds). Wintrobe's Clinical Hematology. 9th ed. London:Lea&Febiger, 1993; 1329-1355.
Albayrak D, Islek I, Kalaycı AQ, Gurses N. Acute ITP; a comparative study of very high dose methylprednisolone and IVIG. J Pediatr 1994;125(6 Pt 1): 1004-1007.
Kuhne T, Buchanan QR, Zimmerman S et al. A prospective comparative study of 2540 infants and children with newly diagnosed ITP from the Intercontinental Childhood ITP Study Group. J Pediatr 2003; 143(5): 605-608.
Yenicesu I, Yetkin S, Ozyurek E, Aslan D. Virus-associated ITP in childhood. Pediatr Hematol Oncol 2002; 19(6): 433-437.
Olcay L, Yetkin S. Trombosito